Structure Therapeutics (GPCR) just moved its obesity pipeline up a gear by kicking off a first in human Phase 1 trial for ACCG-2671, its oral amylin receptor agonist targeting metabolic disease. See ...
Healthcare dealmakers head to San Francisco hoping for megamergers in 2026 Healthcare dealmakers are heading to San Francisco this weekend betting on a new wave of mega-mergers in 2026 that could ...
A new study involving the Medical University of Vienna shows how the multi-resistant fungus Candida auris utilizes carbon dioxide (COâ‚‚) to survive on the skin and become resistant to antifungal ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback